HCW Biologics Inc. (NASDAQ:HCWB) Sees Significant Decrease in Short Interest

by · The Markets Daily

HCW Biologics Inc. (NASDAQ:HCWB – Get Free Report) saw a significant decline in short interest in October. As of October 15th, there was short interest totaling 37,709 shares, a decline of 38.1% from the September 30th total of 60,941 shares. Approximately 1.9% of the company’s stock are short sold. Based on an average trading volume of 226,124 shares, the short-interest ratio is presently 0.2 days.

Analysts Set New Price Targets

A number of research firms have recently weighed in on HCWB. Wall Street Zen upgraded shares of HCW Biologics from a “sell” rating to a “hold” rating in a report on Saturday. Weiss Ratings reiterated a “sell (e+)” rating on shares of HCW Biologics in a report on Thursday, October 15th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $30.00.

Get Our Latest Stock Report on HCW Biologics

HCW Biologics Trading Up 1.8%

HCWB traded up $0.02 during trading on Monday, hitting $1.12. The stock had a trading volume of 51,285 shares, compared to its average volume of 1,166,428. The firm has a market cap of $2.51 million, a PE ratio of -0.04 and a beta of 2.31. HCW Biologics has a 12 month low of $1.09 and a 12 month high of $23.94. The company has a 50 day simple moving average of $1.92 and a 200-day simple moving average of $4.16.

HCW Biologics (NASDAQ:HCWB – Get Free Report) last released its quarterly earnings results on Friday, August 14th. The company reported ($11.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.98) by ($9.60). The firm had revenue of $0.14 million for the quarter, compared to the consensus estimate of $0.14 million. HCW Biologics had a negative net margin of 83.03% and a negative return on equity of 262.33%.

HCW Biologics Company Profile

(Get Free Report)

HCW Biologics Inc (NASDAQ: HCWB) is a clinical-stage biotechnology company focused on developing immunotherapies for diseases associated with chronic inflammation, immune dysfunction and aging. The company’s research is intended to address conditions in which persistent inflammation contributes to disease progression.

HCW Biologics uses its proprietary TOBI platform to design multifunctional fusion proteins that can target inflammatory pathways and modify immune responses. Its development programs have included HCW9218, an investigational immunotherapy designed to combine immune-stimulating activity with inhibition of transforming growth factor beta, a signaling pathway associated with immune suppression and disease progression.

See Also